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Exosomes and microvesicles (EMV) are lipid bilayer-enclosed structures, released by
cells and involved in intercellular communication through transfer of proteins and genetic
material. EMV release is also associated with various pathologies, including cancer,
where increased EMV release is amongst other associated with chemo-resistance
and active transfer of pro-oncogenic factors. Recent studies show that EMV-inhibiting
agents can sensitize cancer cells to chemotherapeutic agents and reduce cancer
growth in vivo. Cannabidiol (CBD), a phytocannabinoid derived from Cannabis sativa,
has anti-inflammatory and anti-oxidant properties, and displays anti-proliferative activity.
Here we report a novel role for CBD as a potent inhibitor of EMV release from three
cancer cell lines: prostate cancer (PC3), hepatocellular carcinoma (HEPG2) and breast
adenocarcinoma (MDA-MB-231). CBD significantly reduced exosome release in all
three cancer cell lines, and also significantly, albeit more variably, inhibited microvesicle
release. The EMV modulating effects of CBD were found to be dose dependent (1
and 5 µM) and cancer cell type specific. Moreover, we provide evidence that this may
be associated with changes in mitochondrial function, including modulation of STAT3
and prohibitin expression, and that CBD can be used to sensitize cancer cells to
chemotherapy. We suggest that the known anti-cancer effects of CBD may partly be
due to the regulatory effects on EMV biogenesis, and thus CBD poses as a novel and
safe modulator of EMV-mediated pathological events.
Keywords: exosomes, microvesicles (MVs), cannabidiol (CBD), peptidylarginine deiminase (PAD), cancer,
inflammation, mitochondria, combinatory treatment
INTRODUCTION
Extracellular vesicles released from cells are classified into exosomes, microvesicles and apoptotic
bodies (György et al., 2011). Exosomes and microvesicles (EMVs) are lipid-bilayer structures
that carry molecules characteristic of their parental cells to recipient cells, mediating intercellular
communication and affecting various physiological and pathological processes including cell
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migration, differentiation and angiogenesis (Ansa-Addo et al.,
2010; Muralidharan-Chari et al., 2010; Turola et al., 2012;
Colombo et al., 2014; Batrakova and Kim, 2015; Kholia et al.,
2016).
Microvesicles (MVs) are phospholipid-rich cell-membrane
derived vesicles (100–1000 nm) released as part of normal
physiology as well as during apoptosis or upon stimulation
(Piccin et al., 2007; Inal et al., 2013). The release of MVs can
be mediated via calcium ion influx through stimulation of cation
channels such as the ATP-gated P2X7, through pores created by
sublytic complement, or via calcium released by the endoplasmic
reticulum (Turola et al., 2012; Raposo and Stoorvogel, 2013;
Stratton et al., 2015a,b). This increase in cytosolic calcium
results in cytoskeletal reorganization and membrane asymmetry,
followed by subsequent MV blebbing (Inal et al., 2012, 2013;
Kholia et al., 2015; Kosgodage et al., 2017; Tricarico et al.,
2017). MV formation can also be caused by mitochondrial stress,
which leads to increased membrane permeability and leakage
of reactive oxygen species (ROS), cytochrome C and apoptosis
inducing factor into the cytoplasm. This results in the formation
of the apoptosome – which, during pseudoapoptosis, can be
formed into MVs for the export of hazardous agents (Inal et al.,
2013).
Exosomes (30–100 nm) are generated intracellularly as they
are formed after the invagination of the endosome membrane,
resulting in intraluminal vesicle formation and the appearance
of multivesicular endosomes, which then release exosomes from
the plasma membrane via exocytosis (Kowal et al., 2014; van
Niel et al., 2018). Crucial cellular components for exosomal
biogenesis are ESCRT (endosomal sorting complexes required
for transport), sphingolipid ceramide, syntetin and syndecan, and
tetraspanins (Théry et al., 2002; Baietti et al., 2012; Colombo et al.,
2013; Costa, 2017; Hessvik and Llorente, 2018). The secretion of
exosomes is also affected via purinergic receptors such as P2X7
(Qu et al., 2007), by microenvironmental pH (Federici et al.,
2014) and calcium (Savina et al., 2003; Kramer-Albers et al.,
2007).
Exosome and microvesicles are emerging as novel therapeutic
targets in treatment of disease as they have been shown to
contribute to inflammatory processes (Foers et al., 2017) and
the progression of numerous pathologies including autoimmune
diseases (Antwi-Baffour et al., 2010; Withrow et al., 2016; Perez-
Hernandez et al., 2017), cancers (Luga et al., 2012; Jorfi et al.,
2015; Kholia et al., 2015; Stratton et al., 2015a; Sung et al.,
2015; Tkach and Théry, 2016; Moore et al., 2017; Sung and
Weaver, 2017) and neurodegenerative diseases (Colombo et al.,
2012; Gupta and Pulliam, 2014; Porro et al., 2015; Basso and
Bonetto, 2016). In cancer patients, elevated EMV levels have
for example been demonstrated in the blood (Ginestra et al.,
1998; Kim et al., 2003; Zwicker et al., 2009) and EMVs can also
aid tumor spread and survival as they transport various micro
RNAs, pathological growth factor receptors and soluble proteins
(Muralidharan-Chari et al., 2010; Inal et al., 2012; Hoshino
et al., 2015). Circulating EMVs in various body fluids such
as cerebrospinal fluid, urine and blood, may in addition serve
as reliable biomarkers of pathophysiological processes (Piccin
et al., 2007; Inal et al., 2012, 2013; Porro et al., 2015). Besides
contributing to disease pathology, EMVs are being considered as
therapeutic vehicles themselves (György et al., 2015; Moore et al.,
2017).
It has been shown that EMV shedding from cancer cells
aids increased active drug eﬄux and thus contributes to their
resistance to chemotherapeutic agents (Bebawy et al., 2009; Tang
et al., 2012; Jorfi and Inal, 2013; Pascucci et al., 2014; Jorfi et al.,
2015; Saari et al., 2015; Soekmadji and Nelson, 2015; Aubertin
et al., 2016; Koch et al., 2016; Muralidharan-Chari et al., 2016).
Recent studies on pharmacological inhibition of EMV release
have shown that such interventions could be a new strategy to
render cancer cells more susceptible to anticancer drug treatment
(Tang et al., 2012; Federici et al., 2014; Jorfi et al., 2015; Koch
et al., 2016; Muralidharan-Chari et al., 2016; Kosgodage et al.,
2017). Such approaches have recently been shown to be effective
in vivo, demonstrating that the application of EMV inhibitors can
effectively sensitize tumors to chemotherapy (Jorfi et al., 2015;
Koch et al., 2016; Muralidharan-Chari et al., 2016), reduce drug
eﬄux (Federici et al., 2014; Koch et al., 2016; Muralidharan-Chari
et al., 2016) and reduce the dose of anti-cancer drug required to
limit tumor growth in vivo (Jorfi et al., 2015). Pharmacological
non-toxic agents that can selectively manipulate extracellular
vesicle release may thus be relevant not only to cancer but also
to other pathologies involving EMV release (Lange et al., 2017).
Cannabidiol (CBD) (Mechoulam et al., 2002), a
phytocannabinoid derived from Cannabis sativa, is anxiolytic
(Blessing et al., 2015) and has analgesic, anti-inflammatory,
antineoplastic and chemo-preventive activities (Martin-Moreno
et al., 2011; Pisanti et al., 2017). CBD has been shown to
have a plethora of molecular targets, including the classical
endocannabinoid system, while effects that do not involve the
classical cannabinoid system are also gaining increased attention
(Ibeas Bih et al., 2015; Pisanti et al., 2017). CBD is generally safe at
therapeutic doses, shows biphasic effects on the immune system,
and has demonstrated anti-cancer activity in vivo (Bergamaschi
et al., 2011; Massi et al., 2013; Haustein et al., 2014; Velasco
et al., 2016). Critically, CBD has been shown to be effective
in various EMV-linked pathologies (Velasco et al., 2016), and
seems to modulate mitochondrial function, including ATP, ROS
and proton leak, as well as uptake and release of calcium (Ryan
et al., 2009; Mato et al., 2010; Rimmerman et al., 2013; Cui et al.,
2017). These observations may be relevant as mitochondria are
key in modulating calcium signaling (Szabadkai and Duchen,
2008; Rizzuto et al., 2012) and importantly, altered calcium
signaling and mitochondrial function are hallmarks of many
cancers (Boland et al., 2013; Stefano and Kream, 2015; Monteith
et al., 2017). This study therefore aimed to investigate putative
modulatory effects of CBD on EMV release and to further
establish whether CBD had combinatory effects with the recently
described EMV-inhibitor Cl-amidine (Luo et al., 2006; Kholia
et al., 2015; Kosgodage et al., 2017). For proof of principle we
used three cancer cell lines, prostate cancer (PC3), hepatocellular
carcinoma (HEPG2) and breast adenocarcinoma (MDA-
MB-231). Here we show effects of CBD on EMV release, on
mitochondrial function, as well as on STAT3 expression, which
amongst other is associated with mitochondrial respiration and
Ca2+ regulation in the mitochondrion (Wegrzyn et al., 2009;
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Yang et al., 2015; Yang and Rincon, 2016), alongside modulatory
effects on prohibitin, a pleiotropic protein involved in cellular
proliferation and mitochondrial housekeeping (Peng et al., 2015;
Ande et al., 2017). Our findings suggest a new link between the
emerging understanding of anti-cancer effects of CBD and its
modulatory effects on EMV biogenesis in cancer cells, described
here for the first time.
MATERIALS AND METHODS
Cell Cultures
Human prostate adenocarcinoma (PC3 and ECACC), human
hepatocellular carcinoma (HEPG2 and ECACC) and human
breast adenocarcinoma (MDA-MB-231; a kind gift from Dr T.
Kalber, UCL) cell lines were maintained at 37◦C/5% CO2, in
growth medium containing 10% EMV-free Foetal Bovine Serum
(FBS) and RPMI (Sigma, United Kingdom). The cells were
split every 3–5 days, depending on confluence, washed twice
with EMV-free Dulbecco’s Phosphate Buffered Saline (DPBS),
prepared as described before (Kosgodage et al., 2017) and
detached by incubation for 10–15 min at 37oC with 0.25%
(v/v) trypsin/EDTA, followed by two washes by centrifugation
using EMV-free DPBS at 200 g/5 min. Before the start of every
experiment, cell numbers and viability were determined by Guava
ViaCount assay (Guava Millipore) and exponentially growing
cells with viabilities of ≥95% were used.
Cell Viability Assays
The Guava EasyCyte 8HT flow cytometer (Millipore) and
ViaCount assay (Guava Millipore) were used to count and
determine viability of cells before the start of every experiment
and to assess cell viability after treatment with EMV inhibitors, as
previously described (Jorfi et al., 2015; Kosgodage et al., 2017).
Cell viability after cisplatin treatment (see 2.9) was assessed
by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide] assay, performed according to the manufacturer’s
instructions (Sigma, United Kingdom).
Effects on EMV Biogenesis Using CBD
and Cl-Amidine
For assessment of effects of CBD and Cl-amidine on EMV
generation, PC3, HEPG2 and MDA-MB-231 cells were seeded
at a density of 3.8 × 105 cells/well, in triplicate, in 12-well
microtiter plates, using pre-warmed serum- and EMV-free RPMI
1640 (Sigma-Aldrich, United Kingdom). To ensure that the
medium was EMV free, it was centrifuged at 70,000 g/24 h and
filtered through a 0.22 µm pore size membrane before use. For
testing of putative inhibitory or modulatory effects on EMV
release, the cells were then incubated with CBD (1 or 5 µM),
Cl-amidine (50 µM) or with a combination of CBD (5 µM)
and Cl-amidine (50 µM), for 60 min at 37◦C/5% CO2, while
control cells were treated with either DMSO (0.001%) or PBS for
CBD and Cl-amidine, respectively. The following concentrations
of CBD (GW Pharmaceuticals, United Kingdom) were used: 1
or 5 µM in 0.001% DMSO, based on clinically relevant doses
for CBD (Bergamaschi et al., 2011); while Cl-amidine (a kind
gift from Prof P.R. Thompson, UMASS) was used at 50 µM
concentration (in PBS) as previously determined as an optimal
dose for maximum EMV inhibition in several cancer cell lines
(Kholia et al., 2015; Kosgodage et al., 2017). For testing of a
combinatory effect on EMV release, CBD was applied at 5 µM
together with Cl-amidine at 50 µM concentrations. After the 1 h
incubation period, the supernatants from each well were collected
from the cell preparations, transferred to sterile 1.5 ml Eppendorf
tubes (kept on ice) and centrifuged at 200 g for 5 min at 4◦C to
remove the cell debris. The resulting supernatants were kept on
ice and subsequently treated for isolation of EMVs, as described
below, to include both exosomes and MVs based on previously
established protocols (Lötvall et al., 2014; Kholia et al., 2015;
Kosgodage et al., 2017; Witwer et al., 2017).
Isolation of EMVs
Exosome and microvesicles were isolated from the CBD,
Cl-amidine, and CBD plus Cl-amidine treated cell culture
supernatants, as well as from the control treated cells (DMSO
or PBS), by differential centrifugation as follows: First, whole
cells were removed by spinning at 200 g/5 min at 4◦C. The
supernatants were then collected and further centrifuged at
4,000 g for 60 min at 4◦C, to remove cell debris. The resulting
supernatants were thereafter collected and centrifuged again at
25,000 g for 1 h at 4◦C. The resulting EMV pellets were collected
and the supernatants were discarded. Next, the isolated EMV
pellets were resuspended in sterile-filtered (0.22 µm) EMV-
free Dulbecco’s PBS (DPBS) and thereafter centrifuged again at
25,000 g for 1 h at 4◦C to remove proteins that may have bound to
the EMV surface. The DPBS supernatant was thereafter discarded
and the resulting isolated EMV pellets were resuspended in
200 µl of sterile EMV-free DPBS for further nanoparticle
tracking analysis (NTA), using the Nanosight (LM10; Nanosight,
Amesbury, United Kingdom). Each experiment was repeated
three times and performed in triplicate.
Nanoparticle Tracking Analysis (NTA,
NanoSight LM10)
To determine size distribution of isolated EMVs, nanoparticle
tracking analysis (NTA), based on the Brownian motion of
vesicles in suspension (Soo et al., 2012), was used. A Nanosight
LM10, equipped with a sCMOS camera and a 405 nm diode
laser, was used to enumerate the EMVs. The NTA software 3.0
was used for data acquisition and processing according to the
manufacturer’s instructions (Malvern). The ambient temperature
was set at 23◦C, while background extraction and automatic
settings were applied for the minimum expected particle size,
minimum track length and blur. For calibration, silica beads
(100 nm diameter; Microspheres-Nanospheres, Cold Spring, NY)
were used. The samples were diluted 1:50 in sterile-filtered, EMV-
free DPBS. To maintain the number of particles in the field
of view approximately in-between 20 and 40, the minimum
concentration of samples was set at 5 × 107 particles/ml. For
capturing, the screen and camera gain were set at 8 and 13,
respectively; while for processing, the settings were at nine
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and three for screen gain and detection threshold, respectively,
as according to the manufacturer’s instructions (Malvern).
Five× 30 s videos were recorded for each sample, measurements
with at least 1,000 completed tracks were used for analysis and the
resulting replicate histograms were averaged. Each experiment
was repeated three times and performed in triplicate.
For verification of the presence of exosomes within the 30–
100 nm sized vesicle peak, according to NTA analysis, and
MVs within the 101–900 nm sized vesicle peak, according to
NTA analysis (Supplementary Figures 1A,B), MVs were pelleted
first, from the EMV supernatants, by centrifugation at 11,000 g
for 30 min at 4◦C, and thereafter the presence of MVs was
assessed by flow cytometry for Annexin V-FITC binding as
a measure of phosphatidylserine exposition characteristic for
MVs (Supplementary Figure 1C). The remaining supernatant
was further centrifuged for the isolation of the smaller sized
exosomes (<100 nm) at 100,000 g for 1 h at 4◦C, using
the Beckman-Coulter Type 60 Ti rotor. Exosomes were then
characterized by Western blotting for the exosome marker CD63
(Supplementary Figure 1D). Exosomes and MVs were also
verified by transmission electron microscopy (Supplementary
Figures 1A,B) according to previously described methods and
recommendations (Ansa-Addo et al., 2010; Lötvall et al., 2014;
Stratton et al., 2015a; Kosgodage et al., 2017; Witwer et al., 2017).
Western Blotting Analysis for Changes in
Exosome-Associated CD63 Expression
HEPG2, PC3, and MDA-MB231 cells were grown as a monolayer
in T75 flasks (Nunc, United States) until approximately 80%
confluent. The media was removed, the cells washed in DPBS and
fresh medium added, containing 5 µM CBD or 0.001% DMSO
as control treatment. After 1 h incubation with CBD or DMSO,
respectively, the media containing EMVs was removed and first
centrifuged at 4000 g for 30 min at 4◦C for removal of cell debris.
The resulting supernatant was thereafter ultra-centrifuged for 1 h
at 100,000 g at 4◦C, collecting the resulting EMV pellet, which
was washed in 500 µl DPBS and subsequently ultra-centrifuged
again at 100,000 g for 1 h at 4◦C. The isolated EMV pellets
were thereafter subjected to protein extraction, using 50 µl RIPA
buffer (Sigma, United Kingdom; supplemented with protease
inhibitor cocktail P8340, Sigma United Kingdom), per pellet, by
pipetting up and down 20 times and thereafter incubating the
pellets in RIPA+ buffer on a shaking platform for 1 h on ice.
Thereafter, extracted proteins were isolated by centrifugation at
16,000 g for 20 min at 4◦C, collecting the protein containing
supernatant. The corresponding HEPG2, PC3, and MDA-MB231
cells were also collected from each flask for internal comparison
of cell amount (as estimated by β-actin) versus vesicles released
between CBD treatment and DMSO controls. Cell pellets were
treated with equal amounts of RIPA+ buffer using 50 µl buffer
per pelleted cells from each flask. Cell protein isolates were then
prepared in the same way as EMV protein isolates. The resulting
EMV and cell protein preparations were then reconstituted
1:1 in 2× Laemmli sample buffer (BioRad, United Kingdom)
containing 5% β-mercaptoethanol (BioRad) and boiled at 100◦C
for 5 min before protein separation on 4–20% Mini-Protean
TGX gels (BioRad). For each EMV sample 20 µl were loaded,
while for each cell lysate preparation, 10 µl were loaded per
lane. For immunoblotting, proteins were transferred to 0.45 µm
nitrocellulose membranes (BioRad) using semi-dry Western
blotting at 15 V constant for 1 h, even transfer was assessed
using Ponceau S staining (Sigma) and the membranes were
blocked in 5% bovine serum albumin (Sigma) in tris-buffered-
saline (TBS) containing 0.01% Tween-20 (Sigma) for 1 h at
room temperature. Incubation with anti-human CD63 (ab68418,
Abcam, United Kingdom, 1/1000 in TBS-T) was carried out
overnight at 4◦C, thereafter the blots were washed three times for
10 min in TBS-T and incubated thereafter in secondary antibody
(HRP-conjugated anti rabbit IgG1, 1/4000, BioRad) for 1 h at
room temperature. The blots were washed five times for 10 min
in TBS-T, followed by one wash in TBS before visualization
with ECL (Amersham, United Kingdom). Membranes were
imaged using the UVP transilluminator (UVP BioDoc-ITTM
System, United Kingdom). For quantitative comparison of CD63
positive vesicles released from each cell line in the presence of
CBD versus DMSO control, the amount of β-actin (ab20272,
Abcam, 1/5000 in TBS-T) expression in the corresponding cell
preparations was compared by densitometry, using ImageJ. The
absence of actin in exosome samples was also tested to verify
a lack of contamination by cellular debris in the exosome
isolates.
Western Blotting Analysis for Cellular
Changes in Mitochondrial Associated
Prohibitin and STAT-3 Expression in
Response to CBD Treatment
Protein isolates from HEPG2, PC3 and MDA-MB231 cells
were prepared, separated by SDS–PAGE and immunoblotted as
described above (2.6). To assess changes in two mitochondrial
associated proteins, prohibitin and STAT3, following CBD
treatment, the membranes were incubated with anti-prohibitin
antibody (ab75771, Abcam; 1/2000 in TBS-T) and anti-STAT3
(phospho Y705) antibody (ab76315, Abcam; 1/2000 in TBS-T).
The secondary antibody was HRP-conjugated anti rabbit IgG1
(BioRad; 1/4000). For internal loading control, β-actin (ab20272,
Abcam, 1/5000 in TBS-T) was used, and detection of prohibitin
and STAT3 expression was normalized against β-actin expression
by densitometry analysis using ImageJ.
Cellular Respiration and Mitochondrial
Function Analysis
Cellular respiration was measured in MDA-MB-231 and
PC3 cancer cells using the Seahorse Bioanalyser according
to the manufacturer’s instructions (Seahorse Biosciences,
United States). The sensor cartridge was hydrated with
Seahorse sensor media (Seahorse Biosciences) 18 h prior to
the assay. In brief, mitochondrial respiration, as determined
by oxygen consumption rate (OCR) was measured by seeding
cells 2.5 × 104 cells/well (for MDA-MB-231) or 4 × 104
cells/well (for PC3) in specific 24 well Seahorse Bioanalyser
plates (Seahorse Biosciences), 24 h prior to the cell respiration
assay. Cells were treated with CBD (1 or 5 µM) for 1 h,
followed by washing in Seahorse Assay medium (Seahorse
Frontiers in Pharmacology | www.frontiersin.org 4 August 2018 | Volume 9 | Article 889
fphar-09-00889 August 10, 2018 Time: 17:44 # 5
Kosgodage et al. Cannabidiol Inhibits Exosomes in Cancer
Biosciences) supplemented with glucose and 1% sodium
pyruvate, pH 7.4 at 37◦C. Thereafter, oligomycin, carbonyl
cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP, 0.2 µM)
and antimycin/rotenone (0.25 µM) were added to the sensor
plate prior to the commencement of calibration and the assay.
Calculations were normalized to protein level, as calculated by
Bradford assay directly after the experimental procedure. Each
experiment was repeated 3–5 times, with technical replicates of
four per plate.
Effect of CBD on Cisplatin-Mediated
Apoptosis of HEPG2 and MDA-MB231
Cancer Cells
HEPG2 and MDA-MB231 cells were grown as a monolayer in
T75 flasks (Nunc, United States) until 80% confluent. The media
was removed, the cells washed in DPBS and fresh medium added,
containing 1 or 5 µM CBD, for 24 h. Medium containing 0.001%
DMSO was used as control treatment. After 1 h incubation
with the compounds, the media was removed, cells gently
washed with DPBS and incubated with 100 µM cisplatin (Sigma,
United Kingdom), dissolved in culture media, for further 24 h.
Cell viability assessment was carried out by MTT assay. The
optical density was measured as a percentage of untreated cells
and repeated 3–5 times per cell type for experimental replicates,
with five technical replicates per plate.
Statistical Analysis
Graphs were prepared and statistical analysis performed using
GraphPad Prism version 6 (GraphPad Software, San Diego, CA,
United States). A one-way ANOVA was performed with Tukey’s
post hoc analysis. Differences were considered significant for
p ≤ 0.05 (∗p ≤ 0.05; ∗∗p ≤ 0.01; ∗∗∗p ≤ 0.001; ∗∗∗∗p ≤ 0.0001).
RESULTS
Effects of CBD on Cancer Cell Viability
Cancer cell viability was not significantly affected by the levels of
CBD used in these experiments after 1 h incubation (Figure 1).
In PC3 cells, 1 µM CBD resulted in a 5.6% decrease in cell
viability (p = 0.1583), and 5 µM CBD in a 2.2% decrease in
cell viability (p = 0.7247) compared to DMSO treated control
cells. The same was observed for HEPG2 cells, with both 1 and
5 µM CBD causing 1.18% decreased cell viability (p = 0.1890 and
p = 0.2746, respectively) compared to DMSO treated control cells.
CBD did also not affect MDA-MB-231 cell viability significantly
compared to DMSO treated control cells, with a 3.5% decrease
observed in 1 µM CBD (p = 0.7090) and 5.4% decrease in 5 µM
CBD treated cells (p = 0.3081). In comparison, cell viability was
affected to some extent by Cl-amidine (50 µM), which so far
has proven our most effective EMV inhibitor with the lowest
toxicity levels compared to other inhibitors previously tested
(Kosgodage et al., 2017). Cell viability for PC3 cells was reduced
by 20% (p = 0.0005), by 11% for HEPG2 (p = 0.0033) and by
5.3% for MDA-MB-231 (p = 0.0353) in the presence of 50 µM
Cl-amidine compared to PBS treated control cells (Figure 1).
In addition, longer-term (24 h) treatment effects of CBD on
cancer cell viability was further assessed for HEPG-2 and MDA-
MB-231 cells, showing dose-depended reduction in cell viability
compared to control DMSO treated cells as follows: In HEPG2
cells, 1 µM CBD resulted in a 38.8% decrease in cell viability
(p < 0.001), and 5 µM CBD in a 47.2% decrease in cell viability
(p < 0.001) compared to DMSO treated control cells. In MDA-
MB-231 cells, 1 µM CBD resulted in a 12.9% decrease in cell
viability (p < 0.05), and 5 µM CBD in a 35.8% decrease in cell
viability (p < 0.01) compared to DMSO treated control cells
(Supplementary Figure 2).
EMV Release Profiles Vary Between PC3,
HEPG2, and MDA-MB-231 Untreated
Cancer Cells
A range in the total amount of EMVs (<900 nm) released
from the three cancer cell lines used in this study varied
considerably under normal control conditions (untreated cells
in the absence of CBD, Cl-amidine or DMSO; Supplementary
Figure 3). Differences were observed in the proportions of
exosomes (<100 nm) and microvesicles (MVs; 100–900 nm)
released from control treated cells (absence of EMV inhibitors
CBD and/or Cl-amidine). While PC3 cells released the highest
amount of EMVs and similar proportions of exosomes and MVs,
both HEPG2 and MDA-MB-231 released a higher proportion
of MVs versus exosomes (Supplementary Figures 3A,B). In
addition, a range in the proportional release of the two MV
subsets at 100–200 nm and 201–500 nm were observed between
the three cell lines, particularly regarding the 201–500 nm subset
which was proportionally highest in HEPG2 compared to PC3
and MDA-MB-231 cells (Supplementary Figure 3B).
CBD Effectively Inhibits Exosome and
Microvesicle Release From HEPG2 Cells
Pre-treatment of HEPG2 with both 1 and 5 µM CBD, for 60 min
before EMV isolation, resulted in a significant reduction of total
EMV release compared to the DMSO treated control cells (86.7%;
p = 0.0001 and 97.9%; p = 0.0002, respectively) and was more
potent than for Cl-amidine (61.9%; p = 0.0002) compared to
control. When using CBD (5 µM) in combination with Cl-
amidine, a significantly higher inhibition was observed compared
to Cl-amidine alone (p = 0.0058). Compared to control treated
cells the combinatory treatment resulted in a 91.9% reduction of
EMVs (p = 0.0002; Figure 2A).
Further analysis of the NTA data, based on size exclusion,
was performed to elucidate the inhibitory effects of CBD on
the release of exosome-sized vesicles (<100 nm) or MV-sized
vesicles (≥100 nm) (Figures 2B,C). The total EMV vesicles
collected at 25,000 g had been confirmed to be comprised
of MVs and exosomes, as confirmed by separate isolation of
MVs (centrifugation at 11,000 g) and of exosomes (100,000 g)
as identified by the expression of CD63 (strong in exosomes,
negligible in MVs), by phosphatidylserine exposition (higher
in MVs compared to exosomes), and by electron microscopy
(MVs ≥ 100 nm; exosomes <100 nm) according to previously
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FIGURE 1 | CBD does not affect cell viability of PC3, HEPG2, and MDA-MB-231 cells after 1 h treatment. The Guava EasyCyte 8HT flow cytometer (Millipore) and
ViaCount assay were used to count and determine viability of CBD treated cells compared to EMV inhibitor Cl-amidine and DMSO treated control cells after 1 h
incubation (∗p ≤ 0.05;∗∗p ≤ 0.01;∗∗∗p ≤ 0.001).
FIGURE 2 | CBD significantly inhibits total EMV, exosome and MV release from HEPG2 cells. Inhibitory effects of CBD alone and in combination with Cl-amidine on
extracellular vesicle release from HEPG2 cancer cells are presented as histograms which are based on size exclusion analysis by Nanosight Tracking Analysis (NTA).
EMVs represent all vesicles 0–900 nm (A); exosomes are vesicles <100 nm (B); and microvesicles (MV) are 100–900 nm (C). The experiments were repeated three
times and the data presented are mean ± SEM of the results (∗p ≤ 0.05; ∗∗p ≤ 0.01; ∗∗∗p ≤ 0.001; ∗∗∗∗p ≤ 0.0001 versus Control; Differences between CBD and
Cl-amidine treatment group is further indicated as #p ≤ 0.05; ##p ≤ 0.01; ###p ≤ 0.001; ####p ≤ 0.0001).
established protocols [11,14,15, 81,82; see Supplementary
Figure 1].
Analysis of inhibitory effects on exosome sized vesicles
(<100 nm) showed that both concentrations of CBD (1 and
5 µM) were more effective (91.6%; p = 0.0005 and 84.0%;
p = 0.0009; respectively) than Cl-amidine (68.4%; p = 0.0026).
The lower dose of CBD (1 µM) was the most potent inhibitor of
exosome release in this cancer cell type. Combinatory treatment
with 5 µM CBD and Cl-amidine resulted in less exosome
inhibition (57.9% compared to control; p = 0.0039) than any of
the single inhibitor treatments, albeit not statistically significantly
different from Cl-amidine treatment alone (p = 0.1134), while
significantly less compared to CBD alone (p = 0.0039 for 1 µM
CBD; p = 0.0025 for 5 µM CBD; Figure 2B).
The inhibitory effect of CBD on MV-sized vesicle release
(≥100 nm) was significant in HEPG2 cells for both 1 µM (86.1%;
p = 0.0001) and 5 µM (99.6%; p = 0.0001) concentrations of CBD
compared to control cells, with 5 µM CBD being significantly
more effective (p = 0.0001). MV inhibitory effects of Cl-amidine
in comparison were 61.1% compared to control (p = 0.0007),
while combinatory treatment of CBD (5 µM) and Cl-amidine
showed a similar effect on total MV release (96.2%; p = 0.0001)
as CBD alone (Figure 2C).
The histograms from the NTA analysis showed a notable
reduction in the approximately 300 nm (201–400 nm range) peak
in CBD pre-treated HEPG2 cells (Supplementary Figure 4), a
feature also observed in the combinatory treatment with CBD
and Cl-amidine, while this 300 nm (201–400 nm range) peak was
present in Cl-amidine treated cells (Supplementary Figure 4).
Thus the effect of CBD and Cl-amidine on MV release in the 100–
200 and 201–500 nm ranges was further assessed in all three cell
lines used in this study (Figure 5).
While CBD had a strong inhibitory effect on both MV subsets,
Cl-amidine had a much stronger inhibitory effect on the smaller
(100–200 nm) than larger (201–500 nm) MV subset compared to
control treated HEPG2 cells (Figures 5A,B). In the smaller MV
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subset, 5 µM CBD showed a stronger inhibitory effect (99.4%;
p = 0.0003) than 1 µM CBD (82.0%; p = 0.0006) compared
to control. Cl-amidine reduced this smaller subset by 98.1%
(p = 0.0004) compared to control, and combinatory treatment
of 5 µM CBD and Cl-amidine had a 98.2% inhibitory effect
(p = 0.0003) compared to control treated cells (Figure 5A).
For the shedding of the larger 201–500 nm sized vesicles, CBD
was a more effective inhibitor in HEPG2 cells than Cl-amidine,
with 1 µM CBD showing 97.1% (p = 0.0001) and 5 µM CBD
100% (p = 0.0002) inhibitory effect, respectively, compared to
controls. In this larger MV subset, Cl-amidine showed only 30%
inhibition (p = 0.0356) compared to control. The combinatory
application of 5µM CBD and Cl-amidine had a similar inhibitory
effect (99.7%; p = 0.0001) as 5 µM CBD alone (Figure 5B).
CBD Effectively Inhibits Exosome and
Microvesicle Release From PC3 Cells
Pre-treatment of PC3 with both 1 and 5 µM CBD, for 60 min
before EMV isolation, resulted in a significant reduction of total
EMV release compared to the DMSO treated control cells (44.5
and 98.1% reduction of EMV release for 1 and 5 µM CBD,
respectively; p = 0.0149; p = 0.0008, respectively) (Figure 3A).
The inhibitory effect by 5 µM CBD on total EMV release
was greater than observed with our previously most efficient
EMV inhibitor Cl-amidine, which was used for comparison
(p = 0.0001), while Cl-amidine had a significantly stronger EMV
inhibitory effect than 1 µM CBD (p = 0.0001). When using CBD
(5 µM) in combination with Cl-amidine no additive change in
total EMV inhibition was found compared to single inhibitors
(Figure 3A).
Analysis of inhibitory effects on exosome sized vesicles
(<100 nm), showed that both CBD and Cl-amidine significantly
reduced the number of vesicles released compared to control,
untreated PC3 cells (98.0 versus 66.1%; p = 0.0001 and p = 0.0001,
respectively compared to control). A significantly stronger
inhibitory effect was observed for 5 µM CBD than with Cl-
amidine (p = 0.0001), while 1 µM CBD was less effective,
inhibiting exosome release by 51.3% compared to control
(p = 0.0002). Combinatory treatment with 5 µM CBD and Cl-
amidine gave similar results as single CBD (5 µM) inhibitor
treatment (96.6%; p = 0.0001 compared to control) (Figure 3B).
The inhibitory effect of CBD on MV-sized vesicle release
(≥100 nm) was significant for both 1 µM (38.5%; p = 0.0009) and
5 µM (98.1%; p = 0.0001) concentrations of CBD, compared to
non-treated control cells, although 5 µM CBD was significantly
more effective than 1 µM CBD (p = 0.0002). The effect of 5 µM
CBD alone was similar in reducing in MV release as seen for
Cl-amidine compared to control cells (95.6%; p = 0.0001) while
combinatory treatment of CBD (5 µM) and Cl-amidine did not
show a further significant additive effect on MV release (93.6%;
p = 0.0001 compared to control) (Figure 3C).
Next, the effect of CBD and Cl-amidine on MV release in
the 100–200 and 201–500 nm ranges was further assessed for
PC3 cells (Figures 5C,D). MV count in the size range of 100–
200 nm was significantly reduced at similar levels by 5 µM CBD,
Cl-amidine, and CBD (5 µM) in combination with Cl-amidine,
compared to DMSO treated controls (98.8, 95.9, and 94.4%,
respectively; p = 0.0001 for all groups compared to control). CBD
at 1 µM also showed significant inhibition compared to control
(71.8%; p = 0.0007), but significantly less inhibition on this MV
subset than 5 µM CBD alone, Cl-amidine alone or CBD (5 µM)
and Cl-amidine in combination (p = 0.0001, p = 0.0001 and
p = 0.0002, respectively; Figure 5C).
For the shedding of the larger MV subset of 201–500 nm sized
vesicles, CBD was more effective at the lower dose of 1 µM than
at 5 µM (p = 0.0001). Cellular release of this MV subset was
reduced by 92% in 1 µM CBD treated cells (p = 0.0001), and
by 81.2% in 5 µM CBD treated cells (p = 0.0001) compared to
controls, while Cl-amidine alone reduced this subset of MVs by
64.0% (p = 0.0002). When used in combination, 5 µM CBD with
Cl-amidine did not show significant inhibition of this MV subset
compared to control (4% inhibition; p = 0.4250) (Figure 5D).
CBD Effectively Inhibits Exosome and
Microvesicle Release From MDA-MB-231
Cells
Pre-treatment of MDA-MB-231 with both 1 and 5 µM CBD for
60 min before EMV isolation resulted in a significant reduction
of total EMV release compared to the control treated cells
(53.4%; p = 0.0001 and 42.9%; p = 0.0001, respectively) but
was a less potent total EMV inhibitor than Cl-amidine (75.9%;
p = 0.0001 compared to control). When using CBD (5 µM) in
combination with Cl-amidine, a significantly (p = 0.0052) higher
inhibition was observed compared to 5 µM CBD alone, while
there was no significant difference compared to 1 µM CBD
treatment (p = 0.2474). Compared to control treated cells the
combinatory treatment resulted in a 55.1% reduction of total
EMVs (p = 0.0006) (Figure 4A)
Analysis of inhibitory effects on exosome sized vesicles
(<100 nm) showed that both concentrations of CBD (1 and
5 µM) were similarly potent at being more effective inhibitors
(97.5%; p = 0.0001 and 99%; p = 0.0001; respectively) than
Cl-amidine (46.7%; p = 0.0001) compared to control treated
MDA-MB-231 cells. Combinatory treatment with 5 µM CBD and
Cl-amidine resulted in similar effects on exosome inhibition as
CBD alone (99.5%; p = 0.0001) (Figure 4B).
The inhibitory effect of CBD on MV-sized vesicle release
(≥100 nm) was significant for both concentrations, albeit less
effective than Cl-amidine. CBD showed 34.4% (p = 0.0001)
inhibition at 1 µM, and 56.5% (p = 0.0001) inhibition at 5 µM,
compared to control, with 5 µM CBD being a significantly more
effective (p = 0.0007) total MV inhibitor. In comparison, MV
inhibitory effects of Cl-amidine were higher, at 77.8% compared
to control (p = 0.0001), while combinatory treatment of CBD
(5 µM) and Cl-amidine showed a similar effect on total MV
release (52.7%; p = 0.0001) as 5 µM CBD alone (Figure 4C)
The effect of CBD and Cl-amidine on MV release in the
100–200 and 201–500 nm ranges was further assessed in MDA-
MB-231 cells (Figures 5E,F). While both concentrations of CBD
showed a significant decrease on the smaller (100–200 nm)
MV subset, the 5 µM CBD concentration showed a stronger
inhibitory effect (77.0%; p = 0.0007) than 1 µM CBD (41.7%;
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FIGURE 3 | CBD significantly inhibits total EMV, exosome and MV release from PC3 cells. Inhibitory effects of CBD alone and in combination with Cl-amidine on
extracellular vesicle release from PC3 cancer cells are presented as histograms which are based on size exclusion analysis by Nanosight Tracking Analysis (NTA).
EMVs represent all vesicles 0–900 nm (A); exosomes are vesicles <100 nm (B); and microvesicles (MV) are 100–900 nm (C). The experiments were repeated three
times and the data presented are mean ± SEM of the results (∗p ≤ 0.05; ∗∗p ≤ 0.01; ∗∗∗p ≤ 0.001; ∗∗∗∗p ≤ 0.0001 versus Control; Differences between CBD and
Cl-amidine treatment group is further indicated as #p ≤ 0.05; ##p ≤ 0.01; ###p ≤ 0.001; ####p ≤ 0.0001).
FIGURE 4 | CBD significantly inhibits total EMV, exosome and MV release from MDA-MB-231 cells. Inhibitory effects of CBD alone and in combination with
Cl-amidine on extracellular vesicle release from MDA-MB-231 cancer cells are presented as histograms which are based on size exclusion analysis by Nanosight
Tracking Analysis (NTA). EMVs represent all vesicles 0–900 nm (A); exosomes are vesicles <100 nm (B); and microvesicles (MV) are 100–900 nm (C). The
experiments were repeated three times and the data presented are mean ± SEM of the results (∗p ≤ 0.05; ∗∗p ≤ 0.01; ∗∗∗p ≤ 0.001; ∗∗∗∗p ≤ 0.0001 versus
Control; Differences between CBD and Cl-amidine treatment group is further indicated as #p ≤ 0.05; ##p ≤ 0.01; ###p ≤ 0.001; ####p ≤ 0.0001).
p = 0.0174), compared to control. Cl-amidine had the strongest
inhibitory effect on this MV subset (84.8%; p = 0.0004), while
the combination of CBD and Cl-amidine showed no significant
change (p = 0.4238) compared to 5 µM CBD alone, reducing
this MV subset by 61.0% compared to control (p = 0.0089)
(Figure 5E).
For the shedding of the larger 201–500 nm sized vesicles, less
inhibitory effects were observed for CBD. Neither CBD alone
nor in combination with Cl-amidine, showed any inhibitory
effects, while Cl-amidine alone reduced the release of this MV
population by 25.7% (p = 0.0004). Contrary to what was observed
in the other two cancer cell lines, CBD increased the release
of this MV subpopulation by 10.5% (p = 0.0143) at 1 µM
concentration and by 84.2% (p = 0.0001) at 5 µM concentration
compared to control – an effect that was somewhat counteracted
in the combinatory treatment with Cl-amidine, where this
CBD-mediated increase was reduced by 42.3% (p = 0.0001),
bringing it down to similar levels as the control treated cells
(Figure 5F).
CBD Modulates CD63 Expression in
HEPG2, PC3, and MDA-MB-231 Cells
Findings from the NTA analysis, showing significant reduction in
EMV release, particularly exosome release, was further assessed
by Western blotting of CD63 expression in all three cancer cell
lines following CBD treatment (5 µM). The expression of CD63
was reduced in all three cell lines following 1 h CBD treatment
(Figure 6), thus confirming the NTA results, showing significant
reduction in exosome biogenesis in response to CBD treatment
in HEPG2 (Figure 6A), PC3 (Figure 6B) and MDA-MB-231
(Figure 6C) cancer cells. The absence of actin in exosome samples
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FIGURE 5 | CBD modulates different MV subpopulations released from PC3, HEPG2 and MDA-MB-231 cells. Inhibitory effects of CBD alone, Cl-amidine or CBD in
combination with Cl-amidine on 100–200 nm and 201–500 nm sized microvesicles, based on size exclusion analysis by Nanosight Tracking Analysis (NTA). Inhibition
of 100–200 nm MV release in (A) PC3; (C) HEPG2; and (E) MDA-MB-231 cancer cells. Inhibition of 201–500 nm MV release in (B) PC3; (D) HEPG2; and
(F) MDA-MB-231 cancer cells. The experiments were repeated three times and the data presented are mean ± SEM of the results (∗p ≤ 0.05; ∗∗p ≤ 0.01;
∗∗∗p ≤ 0.001; ∗∗∗∗p ≤ 0.0001 versus Control; Differences between CBD and Cl-amidine treatment group is further indicated as #p ≤ 0.05; ##p ≤ 0.01;
###p ≤ 0.001; ####p ≤ 0.0001).
was also confirmed to exclude contamination by cellular debris in
the exosome isolates (not shown).
Mitochondrial Function Alteration
Analysis in MDA-MB-231 and PC3 Cells
Following CBD Treatment
Mitochondrial analysis, using the Seahorse Bionalayser,
measured mitochondrial respiration along with several key
mitochondrial factors associated with mitochondrial function
through oxygen consumption (Figure 7). In MDA-MB-231
cells, basal mitochondrial OCR (oxygen consumption rate)
was significantly increased, compared to non-treated controls
(50.4 ± 13.5 pMoles/min), following 1 h CBD treatment at
1 µM (104.1 ± 23.7 pMoles/min; p ≤ 0.05) and 5 µM CBD
(129.6 ± 36.4 pMoles/min; p ≤ 0.05) (Figure 7A). In PC3
cells, basal mitochondrial OCR showed a decreasing trend
with increased dose of CBD, following 1 h CBD treatment at
1 µM (124.2 ± 9.6 pMoles/min; p ≤ 0.05) and 5 µM CBD
(116.3 ± 13.1 pMoles/min), while not statistically significant
compared to non-treated control (146.8 ± 12.9 pMoles/min)
(Figure 7D).
Dose dependent changes in relative ATP production levels
were observed in both cancer cell lines in response to CBD
treatment compared to untreated cells. Compared to untreated
MDA-MB-231 cells (37.5 ± 8.9 pMoles/min), in 1 µM
CBD treated MDA-MB-231 cells ATP production levels were
60.5± 12.8 pMoles/min (p≤ 0.05) and in 5 µM CBD treated cells
ATP production levels were 69.2 ± 16.8 pMoles/min (p ≤ 0.05)
(Figure 7B). PC3 cells showed a decreasing trend in ATP
with increased dose of CBD, albeit not statistically significant
compared to control treated PC3 cells (106.0± 9.4 pMoles/min).
In 1 µM CBD treated PC3 cells ATP production levels were
87.8 ± 9.1 pMoles/min and in 5 µM CBD treated cells ATP
production levels were 81.2± 11.9 pMoles/min (Figure 7E).
A significant dose dependent increase in proton leak was
observed for both concentrations of CBD in MDA-MB-231 cells
as follows: 1 µM CBD: 21.6 ± 3.2 pMoles/min (p ≤ 0.01), and
5 µM CBD: 32.2 ± 9.5 pMoles/min (p ≤ 0.01), compared to
untreated cells (5.8 ± 3.3 pMoles/min) (Figure 7C). In PC3 cells
proton leak was somewhat, but not significantly, reduced in the
presence of 1 µM (36.4 ± 3.6 pMoles/min) and 5 µM CBD
(35.1± 2.8 pMoles/min) compared to untreated cells (40.9± 3.7
pMoles/min) (Figure 7F).
CBD Modulates Expression of
Mitochondrial Associated Proteins
Prohibitin and STAT3
Protein isolates from HEPG2, PC3 and MDA-MB231 cells were
further assessed for changes in two mitochondrial associated
proteins; prohibitin and STAT3, following CBD (5 µM)
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FIGURE 6 | CD63 exosomal marker is reduced following 1 h CBD treatment in HEPG2, PC3, and MDA-MB-231 cancer cells. The results from the NTA analysis
were confirmed by Western blotting for the exosomal CD63 marker, which was reduced in all three cell lines following 1 h treatment with 5 µM CBD: (A) CD63
expression is reduced in CBD treated versus DMSO control treated HEPG2 cancer cells; (B) CD63 expression is reduced in CBD treated versus DMSO control
treated PC3 cells; (C) CD63 expression is reduced in CBD treated versus DMSO control treated MDA-MB-231 cells. All EMV preparations were performed in equal
buffer volume (50 µl) and all cell lysates were prepared in equal buffer volume (50 µl) between all samples, for accurate presentation of amounts of vesicles isolated
and amounts of cells grown and collected per flask. For EMV isolates, 20 µl of sample was loaded per lane, while for β-actin detection in the corresponding cell
lysates, 10 µl of sample was loaded per lane. The relative detection of CD63 in EMVs released from the corresponding cell preparation is indicated by “R,” in relation
to β-actin detection in the corresponding cell isolate, for comparison between CBD treatments versus DMSO control.
treatment and compared to DMSO treated controls. In all three
cancer cell lines, levels of prohibitin were reduced, although
more marked changes were noted in the PC3 (Figure 8A) and
HEPG2 (Figure 8B) cells compared to the MDA-MB-231 cells
(Figure 8C). In all three cancer cell lines, STAT3 (phospho Y705)
was also reduced after 1 h CBD (5 µM) treatment; again this
reduction was higher in PC3 and HEPG2 cells (Figures 8D,E),
compared to the MDA-MB-231 cells (Figure 8F).
CBD Sensitizes HEPG2 and
MDA-MB-231 Cancer Cells to on
Cisplatin-Mediated Apoptosis
In both HEPG2 and MDA-MB-231 cancer cells, CBD increased
cisplatin-mediated apoptosis (Figure 9). In HEPG2 cells,
compared to untreated control cells, cisplatin treatment alone
resulted in 57.3% cell viability (p< 0.01). However, this effect was
significantly enhanced (p< 0.001) if cells were first treated with 1
and 5 µM CBD (54.5 and 39.1%, respectively), prior to cisplatin
(Figure 9A). In MDA-MB-231 cells, compared to untreated
control cells, cisplatin treatment alone resulted in 47.3% cell
viability (p < 0.001), while 21.3 and 8.3% cell viability was
observed for cells treated with 1 or 5 µM CBD prior to cisplatin
treatment (p < 0.01). CBD treatment alone led to significant
changes in cell viability, but to a much lesser extent than those
observed when cells were first treated with CBD followed by
cisplatin (Figures 9A,B).
DISCUSSION
This study reveals a novel finding for CBD; it can selectively
inhibit the release of subsets of EMVs, from cancer cell lines.
The different cancer cell lines tested here (prostate cancer PC3,
hepatocellular carcinoma HEPG2 and breast adenocarcinoma
MDA-MB-231) varied in the proportional amounts of total
EMVs, MVs and exosomes released under standard conditions
(Supplementary Figure 3). Nonetheless, across this range of
EMV release profiles, we found that CBD consistently inhibited
exosome release significantly and also had significant, albeit more
variable, modulating effects on MV release. This novel function of
CBD on EMV release, revealed here for the first time, may be of
high relevance for optimized therapeutic application in various
EMV-mediated pathologies.
There is a considerable interest in using EMV inhibitors to
sensitize cancers to chemotherapy. Previous work, using the
calpain inhibitor calpeptin for MV inhibition, in combination
with chemotherapy drugs fluorouracil and docetaxel, reduced
the effective chemotherapeutic dose needed by 100-fold to
produce comparable reduction in tumor volume in vivo. The
same study also showed that methotrexate is released from
cancer cells in MVs (Jorfi et al., 2015). Similar findings of
drug eﬄux and sensitisation to gemcitabine in response to
MV inhibition were established in pancreatic cancer in vitro
and in vivo upon MV inhibition via ERK-mediated pathways
(Muralidharan-Chari et al., 2016); and to doxorubicin and
pixantrone treatment upon exosome inhibition via inhibition
of ATP-transporter A3 in B-cell lymphoma models (Koch
et al., 2016). Also, chemotaxis of cancer cells has been shown
to be promoted by exosome secretion, but to be diminished
by knockdown of the exosome regulator Rab27a (Sung and
Weaver, 2017). Inhibition of exosome secretion has been shown
to cause defective tumor cell migration (Sung et al., 2015),
while exosomes isolated from gastric tumor cells were shown
to induce tumor cell migration and promotion in receiving
cells (Wu et al., 2016). Previously, our work identified a novel
pathway of MV release involving peptidylarginine deiminases
(PADs) and the effective inhibition of PAD-mediated EMV
release using Cl-amidine (Kholia et al., 2015; Kosgodage et al.,
2017), suggesting implications in a number of pathologies
(Lange et al., 2017). In addition, we have also recently
shown that several new candidate EMV inhibitors, including
bisindolylmaleimide-I, imipramine and Cl-amidine, are more
potent EMV inhibitors than calpeptin (Kosgodage et al., 2017)
and those they sensitize cancer cells to chemotherapeutic agents.
This further call for the identification of novel EMV inhibitors,
which are safe for application in vivo, such as CBD now
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FIGURE 7 | Mitochondrial function alteration following 1 h CBD treatment in MDA-MB-231 and PC3 cancer cells. MDA-MB-231 and PC3 cells were treated with 1
or 5 µM CBD for 1 h prior to mitochondrial functional analysis using the Seahorse Bioanalyser for the following parameters: (A,D) Basal mitochondrial respiration;
(B,E) Quantification of ATP production; (C,F) Proton leak. Data shown is repeated three times (for MDA-MB-231 cells) or five times (for PC3 cells) with four technical
replicates per plate. Data is represented as mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 versus untreated control cells.
identified here. Indeed, as we have shown here, by significantly
increasing cisplatin mediated apoptosis, CBD showed a similar
ability to other EMV inhibitors of sensitizing cancer cells to
chemotherapy.
CBD-mediated inhibition of EMV release, observed in the
present study, was more effective for some EMV subsets and
cancer cells than Cl-amidine, our most potent EMV inhibitor to
date (Kosgodage et al., 2017). One intriguing finding in our study
is the selectivity of CBD on different EMV subsets in the three
different cancer cell lines, which also varied with concentration
(1 and 5 µM). In PC3 cells, 5 µM of CBD was the most
effective inhibitor of total EMVs, exosomes, total MVs and the
smaller MV subset (100–200 nm), while 1 µM CBD was most
effective at inhibiting the larger MV subset (201–500 nm). In
the HEPG2 hepatocellular carcinoma cells 5 µM CBD had the
main impact on total EMV and MV release, while 1 µM CBD
most significantly affected exosome release. Overall, the potency
of CBD to inhibit all subsets of EMVs tested here was most
marked in the HEPG2 cells. In MDA-MB-231 cells the inhibitory
effect of CBD was particularly marked for exosome release, while
total MV release was less inhibited by CBD compared to Cl-
amidine. Recent studies in this invasive breast cancer cell line
have suggested an active role for exosomes in increased cell
movement and metastasis (Harris et al., 2015). The increase in
MVs released in the size range of 201–500 nm in response to
CBD treatment was specific for the MDA-MB-231 cells. This
may indicate a higher sensitivity of this particular cancer cell line
to CBD and may also be a sign of pseudoapoptotic responses,
where increased membrane permeability and leakage of reactive
oxygen species (ROS) and other apoptotic factors is still low
enough for the cell to turn the apoptosome into MVs for export
of hazardous agents (Mackenzie et al., 2005; Inal et al., 2013).
Indeed, a dose-dependent increase in ROS levels in response to
1 h CBD treatment (Supplementary Figure 5) alongside a dose-
dependent increase in proton leak, mitochondrial respiration
and ATP levels (Figures 7A–C) were observed in this cancer
cell line in particular. In the PC3 cells on the other hand, the
reduced EMV release observed in all EMV subsets, tallied in
with a trend of reduced ATP production and reduced proton
leak as well as lowered mitochondrial respiration, indicating an
absence of pseudoapoptotic responses, as clearly reflected also in
the significant reduction of the 201–500 nm MV subset in the PC
cancer cells.
In the current study we have found that while reducing EMVs,
CBD also modulates mitochondrial function and the expression
of mitochondrial associated proteins prohibitin and STAT3.
Although studies on direct links between EMV release and
mitochondrial changes are relatively limited, requiring further
investigation, EMV generation has previously been linked to
this organelle (Mackenzie et al., 2005; Qu et al., 2007; Lopez
et al., 2008; Morel et al., 2010; Dubyak, 2012; Soto-Heredero
et al., 2017). Both changes in mitochondrial calcium buffering
and dynamics, including ROS, ATP and proton leak, have
previously been shown to be linked to MV formation (Mackenzie
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FIGURE 8 | CBD modulates expression of prohibitin and STAT3 in cancer cells. PC3, HEPG2, and MDA-MB-231 cells were tested for changes in mitochondrial
associated prohibitin and STAT3 expression following 1 h treatment with CBD (5 µM). Levels of prohibitin were reduced in all three cancer cell lines while this
reduction was more marked in PC3 (A) and HEPG2 (B) cells compared to MDA-MB-231 (C). STAT3 (phospho Y705) was also reduced after 1 h CBD (5 µM) in both
PC3 (D) and HEPG2 cells (E), while MDA-MB-231 cells showed a similar, albeit less marked trend (F). Beta-actin is shown as an internal loading control and “R”
indicates the change of prohibitin and pSTAT3 expression relative to β-actin levels, respectively, for comparison between CBD treatment and DMSO control.
FIGURE 9 | CBD sensitizes HEPG2 and MD-MB-231 cancer cells to cisplatin-mediated apoptosis. HEPG2 (A) and MDA-MB-231 (B) cells were treated with 1 or
5 µM CBD for 24 h prior to further 24 h incubation with cisplatin (CSP, 100 µM). Cell viability was assessed by MTT assay. Data shown is repeated three times with
three technical replicates per plate. Data is represented as mean ± SEM. ∗p < 0.05, ∗∗p < 0.01 versus untreated control cells.
et al., 2005) and to affect ATP-mediated release of MVs and
exosomes (Qu et al., 2007; Dubyak, 2012). Mitochondrial stress
can also lead to MV formation via pro-apoptotic Bax and Bak,
which insert into the mitochondrial outer membrane resulting
in its depolarisation and increased membrane permeability. This
leads to ROS, cytochrome C (Cyt C) and apoptosis inducing
factor (AIF) leakage into the cytoplasm and eventual apoptosis.
Where apoptosis is triggered by the extrinsic pathway, such as
stimulation of FasL, activation of caspase 8 leads to cleavage
of Bid, tBid then translocating to the mitochondrial membrane,
mediating Cyt C release; this causes cytoskeletal degradation
and formation of the apoptosome (Dale and Friese, 2006; Lopez
et al., 2008; Inal et al., 2012). In scenarios of minimal damage
the cell can use the apoptosome to form a MV and export
the hazardous agents via pseudoapoptosis (Inal et al., 2012).
Furthermore, pseudoapoptosis has been shown to involve rapid
reversible mitochondrial depolarization, mitochondrial swelling
and changes in mitochondrial and cytosolic calcium (Mackenzie
et al., 2005). In cancer cells, a previous study has for example
shown a ten-fold increase in the release of a 333–385 nm MV
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subset in pseudoapoptotic response to sublytic C5b-9 stimulation
(Stratton et al., 2015a). Mitochondrial permeability has been
shown to be important also for MV shedding from platelets,
where the natural phenol and Bax activator gossypol promoted
mitochondrial depolarization, PS exposure and MV release (Dale
and Friese, 2006). As it is now thought that many oncogenes and
tumor suppressors control calcium flow into the mitochondrion,
one key emerging target in cancer treatment is mitochondrial
control of calcium signaling (Danese et al., 2017). Previously,
effects of CBD on modulating mitochondrial calcium buffering
and mitochondrial function have been described (Ryan et al.,
2009; Mato et al., 2010; De Petrocellis et al., 2011; Shrivastava
et al., 2011; Rimmerman et al., 2013; Fisar et al., 2014; Cui et al.,
2017), including on mitochondrial swelling, ROS production and
mitochondrial potential (Mato et al., 2010). STAT3 is indeed
implicated in mitochondrial calcium control (Yang et al., 2015;
Garama et al., 2016; Yang and Rincon, 2016) and the reduction
in STAT3 in cancer cells observed here following CBD treatment
may thus have modulatory effects on EMV release. A reduction
of STAT3 by CBD has previously been shown in glioblastoma
cells where it was for example related to the inhibition of
self-renewal (Singer et al., 2015). Prohibitin is ubiquitously
expressed in many cell types and involved amongst other in
energy metabolism, proliferation and apoptosis (Peng et al.,
2015; Ande et al., 2017). It acts as a scaffold protein in the
inner mitochondrial membrane and is thus important for the
regulation of mitochondrial architecture (Merkwirth et al., 2012).
Prohibitin is critical for mitochondrial house-keeping including
mitochondrial dynamics, morphology and biogenesis as well as
stabilizing the mitochondrial genome (Peng et al., 2015). Here
we show, for the first time, that prohibitin is reduced in cancer
cells following CBD treatment. The slight variability in reduction
of prohibitin in response to CBD between the cancer cell lines
tested here tallies in with the observed differences in effectivity of
CBD to inhibit EMVs from these different cancer cells. A similar
correlation was found between expression changes in STAT3
and inhibition of EMV release following CBD treatment, as
both PC3 and HEPG2 cells showed more reduction in STAT3
levels following CBD treatment, alongside a more pronounced
inhibitory effect on total EMV release, compared to MDA-MB-
231 cells; which, while showing overall significant reduction
in EMVs and reduced levels of STAT3 and prohibitin, these
effects were somewhat less marked than in the other two cancer
types. The EMV modulatory effects of CBD could thus be
partly mediated by the above observed mitochondrial changes.
In addition, CBD has also been shown for example to stimulate
mitochondrial uptake of calcium, followed by a decrease and a
matching sudden increase in intracellular calcium (Ryan et al.,
2009), indicating thus also putative dynamic effects on EMV
release. Notably, in PC3 cells, a CBD-dose-dependent trend was
observed for reduced ATP production, which correlated with
the overall reduction observed in total EMVs, exosomes and
MVs in response to CBD treatment, compared to DMSO treated
control cells. Furthermore, prohibitin has previously been shown
to protect cancer cells from ER stress and chemotherapy-induced
cell death (Cheng et al., 2014; Tortelli et al., 2017). Prohibitin
accumulation in mitochondria and de novo accumulation has
been shown to cause chemoresistance, while knock-down of
prohibitin sensitized cancer cells to chemotherapeutic treatment
(Tortelli et al., 2017). Inhibition of prohibitin has also been
shown to repress cancer cell malignancy progression in hypoxia
(Cheng et al., 2014). The observed reduction in prohibitin
observed here, following CBD treatment, may thus be an
important factor in contributing to the sensitisation of cancer
cells to chemotherapeutic agents, as previously shown for CBD
in glioblastoma (Torres et al., 2011), in addition to affecting EMV
release due to changes in mitochondrial function caused partly by
prohibitin and STAT3 downregulation following CBD exposure.
Using a combined application of CBD (5µM) with Cl-amidine
resulted in different effects on the various EMV subsets and
varied between the three cancer cell lines. In general, Cl-amidine
did not have additive effects on the inhibitory effect of EMV
release compared to CBD alone, while the combinatory treatment
was more effective on some subsets than Cl-amidine alone, as was
observed on exosome release in PC3 cells and on MV release
in HEPG2 cells. However, the difference between cancer cell
types to combinatory treatment did not significantly affect the
larger MV subset in PC3 cells, while both CBD and Cl-amidine
alone did. Similarly, combinatory treatment did not show more
effect than CBD or Cl-amidine alone on exosome release from
HEPG2 cells. Interestingly, in MDA-MB-231 cells, Cl-amidine
counteracted the increased CBD-mediated release observed for
the larger MV subset (201–500 nm), when used in combination,
bringing the amount of vesicles release down to similar levels
as for the control treated cells. Overall our results suggest that
the two EMV inhibitors act on different pathways involved in
MV and exosome release. While previously, Cl-amidine has
been shown to act on MV biogenesis via increased cytoskeletal
actin deimination and nuclear PAD translocation, indicative for
changes in histone deimination (Kholia et al., 2015), CBD may
act in part through modulation of mitochondrial metabolism
as described here. Accordingly, and depending on which EMV
subset is being targeted, our results indicate that tailored
approaches for selective EMV inhibition could be developed for
various EMV mediated pathologies. The expanded repertoire of
EMV inhibiting agents, including CBD now revealed here, along
with its sensitizing effects on cancer cells to cisplatin-mediated
apoptosis, indicates a therapeutic potential for sensitisation of
cancer cells to chemotherapy, as has been demonstrated for other
promising EMV inhibitors (Tang et al., 2012; Federici et al.,
2014; Jorfi et al., 2015; Koch et al., 2016; Muralidharan-Chari
et al., 2016; Kosgodage et al., 2017). Importantly, such EMV-
modulating agents could be used to allow for lower dose of
chemotherapeutic drug for effective inhibition of tumor growth
in vivo (Jorfi et al., 2015; Muralidharan-Chari et al., 2016). The
ability of CBD to inhibit EMV release may indeed be a hitherto
overlooked contributing factor in the beneficial effects of CBD
observed in cancer therapy, where the exact mechanisms still
remain to be unraveled (Torres et al., 2011; Ramer et al., 2012,
2014; Massi et al., 2013; Vara et al., 2013; Haustein et al., 2014;
Velasco et al., 2016; Pisanti et al., 2017), as for example in
glioma models, where CBD has been shown to enhance effects
of temozolomide (Torres et al., 2011). Modulating EMV release
may thus be an important therapeutic approach, also to prevent
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metastasis, where tumor derived exosomes have been shown to
be involved in preparation of the pre-metastatic niche (Hoshino
et al., 2015).
CONCLUSION
A new mode of action for CBD in cancer, via modulation of EMV
release, is revealed here for the first time. The findings presented
in this study serve as a first proof of principle for CBD-mediated
inhibition and modulation of EMV biogenesis, and shows
cancer-type and dose specific effects. As CBD modulation of
mitochondrial functions is well established, the effects observed
here on changes in EMV release, mitochondrial function and
mitochondrial associated proteins, alongside sensitisation of
cancer cells to cisplatin mediated apoptosis, provide a platform
for further research on detailed mechanistic pathways of CBD’s
mode of action on EMV biogenesis and cellular communication.
Furthermore, this work opens up wide ranging research into
novel therapeutic avenues in EMV-mediated pathologies.
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